MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Allogene Therapeutics, Inc. (NASDAQ: ALLO)*
Organization & Developments: Allogene
Parents
Allogene Therapeutics, Inc. (NASDAQ: ALLO)*
Children
2019: Allogene Moves Forward With CAR-T Therapy Pipeline_seekingalpha.com
2019: Allogene Therapeutics Announces FDA Clearance of the IND for ALLO-715, a BCMA Allogeneic CAR T (AlloCAR T™) Therapy Nasdaq:ALLO
2019: Joining Chang and Belldegrun, Rafael Amado takes a leading R&D post in the next big cell therapy revolution – Endpoints News
2020: Allogene: Cutting Edge Allogeneic CAR-T Therapy Developer
2020: ASCO: Allogene reports 63% response rate in early trial of off-the-shelf CAR-T in lymphoma
2021: Allogene Therapeutics: I Am Buying On The Clinical Hold Dip
2022: Allogene Therapeutics (ALLO) Investor presentation - Slideshow_ seekingalpha.com
2022: Allogene: Possible First Pivotal Study With Allogeneic CAR-T ALLO-501A_ seekingalpha.com
2024: Allogene links off-the-shelf CAR-T to responses and 3 deaths in phase 1 solid tumor trial
2024: Allogene Therapeutics Receives FDA Regenerative Medicine
2024: Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside
2024: Allogene Therapeutics: A Promising Biotech With A Concerning Lag Time Ahead_seekingalpha.com
2024: Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies
2024: Allogene Therapeutics: Showing Promise Despite Some Shaky Safety
2024: Allogene Therapeutics: Showing Promise Despite Some Shaky Safety_ seekingalpha.com
2025: Allogene extends cash runway into 2027 while prioritizing ALPHA3 and clinical momentum
2025: Allogene reports patient death, discontinues investigational antibody in CAR-T pivotal trial
2025: Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment
2025: Allogene Therapeutics: Disrupting CAR-T With A Scalable Model
2025: Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade)
2025: Allogene Therapeutics’ ALLO-329 Cleared by FDA for Phase 1 Clinical Trial in Rheumatology Indications
2025: Allogene Therapeutics’ ALLO-329 Received FDA IND Clearance for Autoimmune Disease Trial
2025: Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities
2025: Allogene’s phase 1 lymphoma data show CAR-T could ‘leapfrog’ competition: analysts_
2025: Can Allogene's $37.3M Diagnostic Partnership Transform Lymphoma Treatment Outcomes?
2026: Allogene Therapeutics’ CAR-T treatment eliminates residual cancer cells in B-cell lymphoma patients_ Allogene’s CAR-T could delay or prevent cancer recurrence
2026: Allogene: If MRD Holds, This Becomes A Completely Different Company
Jumps
*Key People: Allogene
Finance & Acquisitions: Allogene